[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![DermTimesNow Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::55642575.png) Dermatology Times [@DermTimesNow](/creator/twitter/DermTimesNow) on x 31.8K followers
Created: 2025-07-08 17:00:59 UTC

💡 Anabela Cardoso, MD, discussed clinical decision-making around lebrikizumab’s mechanism and dosing flexibility, patient-centered considerations, and Eli Lilly’s ongoing dermatology pipeline.

#DermTwitter #lebrikizumab


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1942630001473458179/c:line.svg)

**Related Topics**
[eli](/topic/eli)
[dermatology](/topic/dermatology)

[Post Link](https://x.com/DermTimesNow/status/1942630001473458179)